



## Diagnostic and Treatment for Three Urological Cancers: Bladder Cancer, Kidney Cancer and Prostate Cancer

Guest Editor:

**Prof. Dr. Tarek A. Bismar**

Cumming School of Medicine,  
University of Calgary, Calgary, AB  
T2N 4N1, Canada

Deadline for manuscript  
submissions:

**closed (20 December 2022)**

### Message from the Guest Editor

Dear Colleagues,

The therapeutic choices available for urological cancers have witnessed significant advancement in recent years, with the new applications of imaging, targeted therapy, and robotic surgery. We are seeking high impact review or research papers for our upcoming Special Issue focusing on diagnosis and treatments of three urological cancers (prostate, bladder, and kidney cancer). Diagnostic options related to molecular signature/platform, AI and novel urine/blood biomarkers related to therapy or molecular subtypes. Therapeutic options relating to new technology or biomarker implementations and selections, as well as those focusing on specific clinical scenarios, such as localized or metastatic disease, are desirable; those describing or implementing novel techniques are also welcome.

Prof. Tarek Bismar  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

---

Cancers Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)